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Abstract
Background: The prevalence and risk of cardiovascular disease increase after menopause in correlation with the
progression of abnormality in the serum lipid profile and the deprivation of estrogen. Erxian decoction (EXD), a
Chinese medicinal formulation for treating menopausal syndrome, stimulates ovarian estrogen biosynthesis. This
study investigates whether EXD improves the serum lipid profile in a menopausal rat model.
Methods: Twenty-month-old female Sprague Dawley rats were treated with EXD and its constituent fractions.
Premarin was administered for comparison. After eight weeks of treatment, rats were sacrificed and the serum
levels of total cholesterol, triglyceride, high-density-lipoprotein cholesterol and low-density-lipoprotein cholesterol
were determined. The hepatic protein levels of 3-hydroxy-3-methyl-glutaryl-CoA reductase and low-density-
lipoprotein receptor were assessed with Western blot.
Results: The serum levels of total cholesterol and low-density-lipoprotein cholesterol were significantly lower in
the EXD-treated group than in the constituent fractions of EXD or premarin groups. However, the serum levels of
triglyceride and high-density-lipoprotein cholesterol were not significantly different from the control groups. Results
from Western blot suggest that EXD significantly down-regulated the protein level of 3-hydroxy-3-methyl-glutaryl-
CoA reductase and up-regulated low-density-lipoprotein receptor. Conclusion EXD improves serum lipid profile in
a menopausal rat model through the suppression of the serum levels of total cholesterol and low-density-
lipoprotein cholesterol, possibly through the down-regulation of the 3-hydroxy-3-methyl-glutaryl-CoA and up-
regulation of the low-density-lipoprotein receptor.
Background
The risk of cardiovascular disease (CVD) and the mor-
tality due to CVD are higher in menopausal women
than their premenopausal counterparts [1,2]. The blood
lipid profile of women deteriorates after menopause.
Derby et al. demonstrated that the serum levels of total
cholesterol (TC), low-density-lipoprotein cholesterol
(LDL-C) and triglyceride (TG) peak at a later stage of
menopause [3]. A sex difference in the expression of
cholesterol regulating enzymes was also found in an ani-
mal model [4], suggesting that the adverse lipid profile
may be related to estrogen deficiency. Administration of
female hormones may produce favorable effects on the
serum lipid profile in postmenopausal women [5].
Erxian decoction (EXD), consisting of Curculigo orch-
ioides (Xianmao), Epimedium brevicornum (Yinyan-
ghuo), Morinda officinalis (Bajitian), Angelica sinensis
(Danggui), Phellodendron chinense (Huangbo) and Ane-
marrhena asphodeloides (Zhimu), has long been used in
Chinese medicine to relieve menopausal symptoms [6].
Our previous study demonstrated that EXD effectively
induces ovarian production of estradiol via the up-regu-
lation of ovarian aromatase, a key enzyme in the bio-
synthesis of estradiol [6]. The antihyperlipidemic
properties exhibited by some bioactive compounds of
EXD further suggest the possible effect of EXD on
improving the blood lipid profile. Ferulic acid from
Angelica sinensis was found to slightly lower liver and
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plasma TC levels in male Sprague Dawley (SD) rats [7].
Mangiferin from Epimedium brevicornum, on the other
hand, significantly decreased serum TC, TG and LDL-C
and increased HDL-C level in an diabetic rat model [8].
Extract of Phellodendron chinense containing various
alkaloids such as berberine, palmatine and jatrorrhizine
reduced the serum levels of TC and LDL-D in a
hypercholesterolemic Wistar rat model [9]. Based on the
estrogenic effect of EXD and the hypolipidemic effects
of its constituent compounds, we would like to know
whether EXD is able to improve the lipid profile in an
well-established menopausal rat model [10].
This study investigates whether EXD improves the
serum lipid profile in a menopausal rat model and the
possible mechanisms involved.
Methods
Herbal materials
EXD was prepared according to our previous study [6].
Petroleum, ethyl acetate, n-butanol, and methanol, of
analytical grade, were purchased from Merck (Ger-
many). HPLC-grade acetonitrile for HPLC analysis was
purchased from Merck (Germany). Double distilled
water was filtered though a 0.22 μm nitrocellulose mem-
brane (Mili Q, USA).
Preparation of EA, BU, WA fractions of EXD and their
quality analysis
Dried EXD powder (1124 g) was decocted in 1.1L of
distilled water at 60°C for 30 minutes and filtered to
remove the insoluble plant residues. The filtrate was
defatted with petroleum ether and then partitioned with
ethyl acetate (EA) and n-butanol (BU) respectively, to
produce three different fractions. The ethyl acetate frac-
tion (EA, 26 g) contained mainly fatty acids, aromatic
acids, quinoids and sesquiterpene according to an HPLC
analysis. The butanol fraction (BU, 109 g) contained
mainly flavonol glycosides, saponin glycosides and ber-
berine-type alkaloids, whereas the remaining aqueous
fraction (WA, 542 g and POLY, 280 g) which accounted
for much of the total EXD weight, contained predomi-
nantly polysaccharides (POLY), monosaccharides, inor-
ganic salt and amino acids.
For evaluation of quality consistency among EXD
extracts and its constituent fractions, three batches (0.5
g powder each) of EXD and its constituent fractions
(BU, EA and WA) were weighed separately and
extracted with 10 ml of 75% methanol in a water bath
at 60°C for 15 minutes, followed by ultrasonication for
30 minutes. Centrifugation of the extracted mixture at
17,700× g (Beckman Coulter, USA) was performed for
15 minutes and the supernatant was saved. The super-
natant was filtered through a 0.45 μm Millex® Syringe
filter unit, and then injected in a volume of 10 μl for
HPLC. Seven standard chemicals including mangiferin,
ferulic acid, icariin, curculigoside, jatrorrhizine, palma-
tine and berberine, which are well-known compounds
in EXD, were employed and compared to the finger-
print of EXD. A reverse-phase column XBridge™ C18
(4.6 mm×250 mm, 5.0 μm, NO. 186003117, Thermo,
USA) connected with a guard column (4.6 mm×7.5, 5.0
μm) was used. The mobile phase consisted of acetoni-
trile (solvent A) and 0.05% sodium dodecyl sulfate
(SDS) in 0.1% acetic acid (solvent B) with a gradient
program of 5-18% solvent A in 0-20 minutes, 18%-30%
solvent A in 20-30 minutes, 30% solvent A in 30-40
minutes, 30-55% solvent A in 40-60 minutes, 55-65%
solvent A in 60-65 minutes, 65-85% solvent A in 65-80
minutes. The flow rate was 1.0 ml per minute. DAD
detector was set at 258, 283 and 345 nm for obtaining
chromatograms with the maximum number of peaks.
UV spectra were obtained from 200 to 400 nm. Chro-
matogram and peak integration were analyzed with
Waters Millennium 32 Chromatography Manager Ver-
sion 3.3 (Waters, USA).
Animals
Twenty-month-old female SD rats with a low serum
estradiol level were employed as a study model. The ani-
mals were purchased at the age of eight months from
Animal Laboratory Units, The University of Hong Kong.
The animals were housed in an air-conditioned room at
an ambient temperature of 24°C and a relative humidity
of 50-65% with automatic 12-hour light-dark cycles. The
experiment was approved by the Committee on the Use
of Live Animals in Teaching and Research (CULATR)
of the Li Ka Shing Faculty of Medicine, The University
of Hong Kong.
Drug administration, serum and organ harvesting
Rats were arbitrarily divided into six groups of 36 ani-
mals. The Chinese medicine extracts were dissolved in
water and fed to the rats through a feeding tube for
eight weeks (EXD: 4.10 g/kg; EA: 0.11 g/kg; BU: 0.470
g/kg; WA: 2.34 g/kg) in a volume of approximately 1
ml. Premarin (PRE, an equine estrogen; 31.25 mg/kg;
0.3 mg of estrogen per capsule) was used as the western
medication group. This dosage was calculated based on
the FDA’s guideline of conversion of animal dose to
human equivalent dose. Body weights of the rats were
measured for dose calculation and drug content was
mixed well to ensure uniform intake. The control
received the same volume of water as EXD. At the end
of the experiments, the animals were anesthetized by an
intraperitoneal injection of ketamine (80 mg/kg) and
xylazine (10 mg/kg) dissolved in 0.9% saline. The sera
and livers were collected and stored at -80°C until
experiments.
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Detection of serum lipid level
The serum lipid level was measured with commercially
available kits from Stanbio Laboratory (USA). The
serum TC, TG, HDL-C and LDL-C levels were mea-
sured with the Stanbio Cholesterol LiquiColor® kit,
Stanbio Triglyceride LiquiColor® kit, Direct HDL-Cho-
lesterol LiquiColor® and Direct LDL-Cholesterol Liqui-
Color® kit respectively, according to the manufacturer’s
instructions.
Immunoblotting analysis of hepatic enzymes
Liver tissues were ground in liquid nitrogen into a fine
powder. Protein was then extracted with RIPA lysis buf-
fer (Sigma-Aldrich, USA) containing a protease inhibitor
mix (GE Healthcare, UK). The mixture was centrifuged
at 15,700× g (Eppendorf, Germany) at 4°C and the
supernatant was retained. The protein concentration
was quantified by the Bradford assay (Bio-Rad, USA).
Protein (120 μg) from each sample was used in SDS-
PAGE and the protein was transferred to a PVDF mem-
brane. The hepatic proteins were probed with anti-LDL-
receptor (ab30532) (Abcam, Hong Kong) and anti-HMG
CoA reductase (sc-27578) (Santa Cruz Biotechnology,
USA) antibodies, with the use of anti-GAPDH antibody
(MAB374) (Millipore, USA) as a housekeeping gene.
The membrane was washed with Tris-buffered saline-
Tween 20 (TBS-T) three times, and then incubated with
horseradish peroxidase-conjugated (HRP) secondary
antibodies (Millipore, USA) in TBS-T buffer for one
hour. The chemiluminescence signal was produced with
an Amersham ECL™ Advance Western Blotting Detec-
tion Kit (GE Healthcare, UK) and detected by a Chemi-
Doc EQ (Bio-Rad, USA) system.
Statistical analysis
To evaluate the effect of EXD on serum lipid profile, we
compared the mean serum lipid level of the treatment
group with the control group by unpaired t-test, with
Welch’s correction for comparison with significantly dif-
ferent variances. Groups treated with EXD’s fractions
were included to demonstrate the contribution of each
fraction to the whole effect of EXD. Differences with P
< 0.05 were considered as statistically significant. The
protein level of the hepatic enzymes was normalized by
comparison with GAPDH, the housekeeping enzyme.
The relative band intensity in Western blotting of the
treatment group was compared with the control group
by unpaired t-test, with Welch’s correction for compari-
son with significantly different variances and P < 0.05
was considered significant. Statistical analysis was con-
ducted with GraphPad Prism 4® (GraphPad Software,
USA).
Results
Quality control
To explore most of the detectable peaks in the HPLC
chromatogram, we investigated the spectra of all eluted
peaks found in the chromatogram of EXD and its frac-
tions using photodiode array detection. The chromato-
grams were generated under the detection wavelengths
of 258, 283 and 345 nm. Chromatographic fingerprint
showing the elution peaks of seven standard compounds
and other common peaks are shown in Figure 1, 2 and
3. Three batches of EXD and its constituent fractions
were examined by HPLC under optimal running condi-
tions. The results are shown in Tables 1, 2 and 3. Inter-
assay relative standard deviation (RSD) values were less
than 5% for all standards. The WA fraction was not
included in the tables as the standard compounds were
not detected.
Effects on lipid profile after EXD treatment
Figure 4 shows that the serum TC level in the meno-
pausal SD rat model decreased significantly after oral
administration of EXD, while the three fractions of
EXD, namely EA, BU and WA, showed no significant
effects. The P value of the EXD group compared with
the control group was less than 0.05 (P = 0.0231, t =
2.204) in 95% confidence interval (CI). A slight albeit
not statistically significant increase of TC level was
observed in the EA, BU and WA groups. Neither was
there a significant decrease of the serum TC level in the
positive control group fed with premarin.
The effects of EXD and its fractions on serum TG
level were not prominent. The serum TG level in all
treatment groups showed no significant changes. The
serum TG levels in the control, EXD and premarin
groups were comparable with each other and slightly
higher than those of EA, BU and WA groups.
Similar to the serum level of TG, all treatment groups
exhibited no statistically significant effects on the serum
level of HDL-C. While the serum HDL-C after EXD
treatment was comparable to the control group, the
HDL-C levels in those of the EA, BU, WA and premarin
groups decreased, although the change was not statisti-
cally significant.
However, oral administration of EXD could bring
about a significant reduction in the serum LDL-C level.
The P value of the EXD group was smaller than 0.05 (P
= 0.0473, t = 1.984) when analyzed by unpaired t-test in
comparison with the control group. The fractions of
EXD, on the other hand, did not elicit significant
changes in the serum LDL-C level. The premarin treat-
ment was also unable to suppress the serum LDL-C
level.
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Effects on protein level of HMG CoA reductase (HMGCR)
and LDL receptor (LDLR) after EXD treatment
To elucidate the underlying mechanism of the effects of
EXD on serum lipid profile, we examined the protein
levels of HMG CoA reductase and LDLR using Western
blot. The results are summarized in Figure 5.
EXD significantly suppressed the protein level of
HMGCR (P = 0.0104, t = 4.556). The EA, BU and
WA fractions of EXD did not significantly decrease
the protein level of HMGCR in comparison with the
control. In the premarin-treated group, the protein
level of HMGCR was comparable to that of the con-
trol group. EXD significantly increased the protein
level of LDLR (P = 0.0308, t = 2.979), while the EA
and PRE treated groups demonstrated a slight albeit
insignificant increase. Protein levels of LDLR in the
WA and BU groups were comparable to that of the
control group.
Figure 1 Comparative chromatograms of EXD and its three different fractions (EA, BU, WA) with seven standard compounds at
different UV detection wavelengths (258 nm) 1. Mangiferin; 2. Ferulic acid; 3. Curculigoside; 4. Icariin; 5. Jatrorrhizine; 6. Palmatine; 7.
Berberine.
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Discussion
The risk of cardiovascular disease in older women is
one of the major concerns in menopausal health man-
agement. It has been reported that about 42% of
women older than 65 years of age exhibit a substantial
increase in serum level of TC, LDL-C [11] and TG [3].
In this study, we investigated the effects of EXD on
serum lipid profiles and its underlying mechanism.
HPLC was used to ensure that there were no variations
in pharmacological effects of EXD due to sample
preparation.
Sample consistency analysis of EXD and its fractions
The comprehensive HPLC chromatograms of EXD and
its fractions were generated and compared with the
peaks of seven standards, mangiferin, ferulic acid, icar-
iine, curculigoside, jatrorrhizine, palmatine and berber-
ine (Figure 1, 2 and 3). These chromatographic
Figure 2 Comparative chromatograms of EXD and its three different fractions (EA, BU, WA) with seven standard compounds at
different UV detection wavelengths (283 nm) 1. Mangiferin; 2. Ferulic acid; 3. Curculigoside; 4. Icariin; 5. Jatrorrhizine; 6. Palmatine; 7.
Berberine.
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Figure 3 Comparative chromatograms of EXD and its three different fractions (EA, BU, WA) with seven standard compounds at
different UV detection wavelengths (345 nm) 1. Mangiferin; 2. Ferulic acid; 3. Curculigoside; 4. Icariin; 5. Jatrorrhizine; 6. Palmatine; 7.
Berberine.
Table 1 Quantification based on chromatograms of three batches of EXD powders (n = 3)
Batch no Mangiferin Ferulic acid Curculigoside Icariin Jatrorrhizine Palmatine Berberine
S1 3.02 0.62 0.45 0.58 0.02 0.64 1.52
S2 3.02 0.63 0.45 0.56 0.02 0.59 1.49
S3 3.00 0.67 0.45 0.53 0.20 0.64 1.47
Mean 3.01 0.64 0.45 0.56 0.02 0.62 1.49
RSD (%) 1.15 2.60 0.36 2.52 0.06 2.77 2.75
The content of compound in EXD powder (μg/mg)
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fingerprints with seven marker compounds were used as
reference standards, indicating the purity, identity and
quality consistency among EXD and its fractions. The
relative standard deviations of the amount of the five
standards were less than 5% in three batches of EXD
and their constituent fractions (Tables 1, 2 and 3), indi-
cating quality consistency among the different batches
of EXD and constituent fractions as well as excluding
the influence of any unknown variability or instability
found in the composition of the active constituents in
the pharmacological test of EXD and its fractions.
The BU fraction (Figure 1, 2 and 3, Table 3) contained
most of the marker chemicals (including fenolic acids,
flavonoids and alkaloids). The relative contents of the
seven marker compounds were much higher compared
with EXD (original formula) (Table 1), while the EA
fraction (Table 2) showed a much higher content of the
small phenols, such as mangiferine and ferulic acid.
Most of the compounds were detected at 283 nm. The
alkaloids (such as berberine, jatrorrhizine and palmatine)
displayed a higher absorption at 345 nm, while phenolic
acid (such as mangiferin and ferulic acid) showed ideal
absorption at 258 nm. The chromatogram of water frac-
tion (WA) at three different UV detection wavelengths
indicated that almost all of the compounds could be
completely extracted with ethyl acetate and n-butanol,
and the residual chemicals in the WA fraction were pre-
sumably some small-molecular-weight metabolites, such
as sugars, amino acids, organic acids and other trace
elements.
Effects of EXD and its fractions on serum lipid profile
The correlation of low estrogen level with serum lipid
profile [11] as well as the stimulatory effect of EXD on
ovarian estrogen synthesis[6] suggest that EXD may
prevent adverse changes in the lipid profile of a meno-
pausal rat model. The serum TC level in the EXD group
was significantly reduced after treatment. The constitu-
ent fractions of EXD were less effective in lowering the
serum TC level. Thus, we suggest that the hypocholes-
terolemic effect of EXD is exerted by the complete for-
mulation of EXD rather than any constituent
compounds. In the premarin-treated group (human
equivalent dosage), the TC level was decreased by an
insignificant degree.
On the other hand, this study found that the effects of
EXD on the serum TG level were insignificant. In all
groups treated with EXD and its constituent fractions,
TG level was slightly increased. Interestingly, the increase
after EXD treatment was less pronounced compared with
its constituent fractions. While EXD did not improve the
serum TG level, it did not lead to an increase of TG as its
bioactive fractions did. In the premarin-treated group,
the TG level was comparable to the control group. The
effect of premarin on the serum TG level was similar
with some other studies of conjugated estrogen on post-
menopausal women, in which conjugated estrogen alone
may increase the circulating TG level [5,12,13].
The effect of EXD on the serum HDL-C level was not
obvious. The serum HDL-C in all groups treated with
EXD or its fractions did not change significantly, while
in the groups treated with the constituent fractions the
serum HDL-C level decreased slightly, thereby worsen-
ing the lipid profile. While EXD cannot improve the
serum HDL-C level, it can prevent the lipid profile from
worsening in comparison with its constituent fractions.
The serum HDL-C level in the premarin-treated group
also decreased slightly.
However, EXD could improve the serum lipid profile
in our study model by decreasing the serum LDL-C
Table 2 Quantification based on chromatograms of three batches of EA powders (n = 3)
Batch no Mangiferin Ferulic acid Curculigoside Icariin Jatrorrhizine Palmatine Berberine
S1 9.19 0.62 0 0 0.01 0.24 0.76
S2 9.13 0.63 0 0 0.02 0.21 0.69
S3 9.16 0.67 0 0 0.11 0.28 0.72
mean 9.16 0.64 0 0 0.01 0.24 0.72
RSD (%) 3.00 3.14 0.25 3.51 3.51
The content of compound in EA powder (μg/mg)
Table 3 Quantification based on chromatograms of three batches of BU powders
Batch no Mangiferin Ferulic acid Curculigoside Icariin Jatrorrhizine Palmatine Berberine
S1 8.18 1.10 0.21 3.12 0.09 2.56 4.78
S2 8.19 0.91 0.26 3.12 0.09 2.49 4.77
S3 8.19 1.05 0.25 3.02 0.09 2.44 4.78
mean 8.19 1.02 0.24 3.09 0.09 2.50 4.78
RSD (%) 0.47 2.40 2.67 5.46 0.08 0.06 0.50
The content of compound in BU powder (μg/mg)
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level. As an increased LDL-C level is a risk factor for
CVD, our results suggested that EXD may be able to
ameliorate the CVD risk in the menopausal model.
Again, effects were observed only in the EXD-treated
group, while the individual constituent fractions did not
significantly reduce the serum LDL-C level. However,
similar to the results on the serum HDL-C, oral admin-
istration of premarin did not improve the serum lipid
profile. The serum LDL-C level in the premarin-treated
group was comparable to the control group and no ben-
eficial effects were noted.
Our results on the serum lipid level showed that EXD
may act as a preventive medicine for reducing CVD risk
in the rat menopausal model by reducing serum TC
level and LDL-C level while preventing the HDL-C and
TG levels from worsening. However, treatment with
premarin did not manifest significant improvement on
the serum lipid profile in the rat model. According to
studies about hormone replacement therapy on meno-
pausal women, supplements with estrogen could
increase the serum HDL-C level and reduce LDL-C
level thus reducing the CVD risk factors [5,12]. One
possible reason is that, the laboratory animals used in
this study were kept in a cage and remained physically
inactive. Physical inactivity is suspected as one of the
risk factors for adverse lipid profile [14]. Therefore, in
the case of this study the hypolipidemic effect of pre-
marin was possibly counteracted. Also, due to different
metabolism between rats and human, the metabolism of
estrone and equilin in premarin may not be the same in
rats and human. Further investigation is needed before
it can be confirmed.
The improvement of lipid profile in the EXD-treated
group but not in the premarin-treated group raises a
question of whether the positive action of EXD is due to
its estrogenic effect or is estrogen-independent. Our
previous study showed that EXD increased the circulat-
ing estrogen level by stimulating ovarian biosynthesis
[6]; however, this study did not indicate whether this
estrogenic effect improved the lipid profile due to the
negative response in the premarin-treated group. In
future studies, 17-beta-estradiol may be used as a posi-
tive control to facilitate comparison. Also, an ovariecto-
mized rat model may be included to for further
Figure 4 Serum concentrations of total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C) and low density
lipoprotein cholesterol (LDL-C) after treatment of old female rats with EXD, its constituent fractions (EA, BU and WA) and premarin
(PRE). The serum concentrations of TC, TG, HDL-C and LDL-C after EXD treatment; Data are presented in mean ± standard deviation (SD), n ≥ 3.
The treatment denoted with * represents P < 0.05 in unpaired t-test compared with control group. Welch’s correction was made for comparison
with significantly different variances. Serum TC level: CTL vs EXD P = 0.0231, t = 2.204. Serum LDL-C level: CTL vs EXD P = 0.0473, t = 1.984
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elucidation of the possible role of stimulated endogen-
ous estrogen production by EXD.
Regulation of HMGCR and LDL-R by EXD at translational
levels
In order to elucidate the underlying mechanism of the
significant improvement in serum profiles of TC and
LDL-C demonstrated by EXD, we examined the protein
levels of HMGCR and LDLR using Western blot. The
levels of HMGCR and LDLR are crucial in maintaining
the TC and LDL-C balance. HMGCR is the rate limiting
enzyme that controls de novo synthesis of cholesterol
through mevalonate pathway [15]. HMGCR catalyses
the conversion of HMG-CoA into mevalonate,
ultimately leading to cholesterol synthesis [16]. LDLR
maintains cholesterol homeostasis by a receptor-recy-
cling pathway, in which circulating LDL-C is returned
into the liver by receptor-mediated endocytosis [16-18].
Only EXD-treated rats displayed a significantly
decreased protein level of HMGCR, indicating a
decrease in the de novo synthesis of TC. The HMGCR
protein levels in the groups treated with other constitu-
ent fractions were comparable to each other and showed
no significant differences from the control. The protein
level of HMGCR in the premarin-treated group was also
comparable to those of the control groups. This is con-
sistent with the results of the serum TC level, which did
not change significantly in the premarin group. In fact,
a previous study suggested that estradiol regulates
HMGCR through the activation of AMP-activated pro-
tein kinase which phosphorylates HMGCR and inacti-
vates its catalytic property [19] rather than acting at the
transcription level.
As the HMGCR level in the EXD-treated group
decreased, it is anticipated that the LDLR level would
rise. From the results, the increase in LDLR protein
level in the EXD-treated group would lead to an ele-
vated clearance of LDL-C, which is in line with the
decreased serum LDL-C level. The effect of the consti-
tuent fractions of EXD was not as pronounced as that
of EXD, suggesting the combined effect of the compo-
nent fractions in EXD. The increase of protein level of
LDL-R in the premarin-treated group was not signifi-
cant, as expected from the results on serum lipid level
and HMGCR level.
Although EXD treatment can significantly suppress
the protein level of HMGCR and elevate LDLR level,
the effect of EXD on the serum TC and LDL-C levels
was not as prominent as that on the relevant regulatory
proteins. Such discrepancy may be attributed to the
complex regulation of HMGCR and LDLR activity.
Moreover, the expression level of HMGCR, the regula-
tion of HMGCR activity involves mechanism such as
phosphorylation/dephsphorylation by AMP-dependent
kinase (AMPK)/protein phosphatase 2A (PP2A); tran-
scriptional regulation of sterol regulatory element-bind-
ing proteins (SREBPs) or protein degradation [15,20].
Pallottini et al. revealed that while the protein level of
HMGCR remained unchanged, its degradation rate
reduced and the enzyme was fully active in aged rats
[15]. Whether the discrepancy between the protein level
and serum lipid profile is related to the above factors
was not assessed in this study.
Our results demonstrated that EXD improved the
serum lipid profile in a rat menopausal model through
the modulation of the protein levels of HMGCR and
LDLR, thus lowering serum TC and LDL-C. Further
studies on the synergistic effects of EXD on serum lipid
Figure 5 Relative intensities of HMG-CoA reductase (HMGCR)
and low density lipoprotein receptor (LDLR) (normalized with
GAPDH in Western blot experiment) after treatment of old
female rats with EXD, its constituent fractions (EA, BU and WA)
and premarin (PRE). The data are presented as mean ± standard
deviation (SD), n ≥ 3. The treatment denoted with * represents P <
0.05 in unpaired t-test compared with control group. Welch’s
correction was made for comparison with significantly different
variances. HMGCR: CTL vs EXD P = 0.0104, t = 4.556. LDLR: CTL vs
EXD P = 0.0308, t = 2.979
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profile and more detailed studies on the mechanisms of
HMGCR and LDLR regulation by EXD will be imple-
mented by us in the near future.
Conclusion
EXD improves serum lipid profile in a menopausal rat
model through the suppression of the serum levels of
total cholesterol and low-density-lipoprotein cholesterol,
possibly through the down-regulation of the HMGCR
and up-regulation of the LDLR.
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